Charlene M. Blake, Ph.D. - Publications
Affiliations: | 2009 | Genetics and Genomics | Duke University, Durham, NC |
Area:
Molecular BiologyYear | Citation | Score | |||
---|---|---|---|---|---|
2011 | Brandal S, Blake CM, Sullenger BA, Fortenberry YM. Effects of plasminogen activator inhibitor-1-specific RNA aptamers on cell adhesion, motility, and tube formation. Nucleic Acid Therapeutics. 21: 373-81. PMID 22103403 DOI: 10.1089/Nat.2011.0320 | 0.567 | |||
2011 | Blake CM, Wang H, Laskowitz DT, Sullenger BA. A reversible aptamer improves outcome and safety in murine models of stroke and hemorrhage. Oligonucleotides. 21: 11-9. PMID 21142878 DOI: 10.1089/Oli.2010.0262 | 0.531 | |||
2009 | Oney S, Lam RT, Bompiani KM, Blake CM, Quick G, Heidel JD, Liu JY, Mack BC, Davis ME, Leong KW, Sullenger BA. Development of universal antidotes to control aptamer activity. Nature Medicine. 15: 1224-8. PMID 19801990 DOI: 10.1038/Nm.1990 | 0.498 | |||
2009 | Blake CM, Sullenger BA, Lawrence DA, Fortenberry YM. Antimetastatic potential of PAI-1-specific RNA aptamers. Oligonucleotides. 19: 117-28. PMID 19284310 DOI: 10.1089/Oli.2008.0177 | 0.542 | |||
2009 | Fortenberry Y, Blake CM, Sullenger BA. Effect of PAI-1 Specific RNA Aptamers On Cell Adhesion and Motility. Blood. 114: 2135-2135. DOI: 10.1182/Blood.V114.22.2135.2135 | 0.606 | |||
2008 | Blake CM, Oney S, Nimjee SM, Sullenger BA. Aptamers and siRNAs in cardiovascular disease Rna Technologies in Cardiovascular Medicine and Research. 255-287. DOI: 10.1007/978-3-540-78709-9_13 | 0.608 | |||
2007 | Blake C, Wang H, Laskowitz D, Sullenger B. ANTIDOTE REVERSAL OF A NOVEL ANTICOAGULANT DECREASES MORTALITY AND IMPROVES NEUROLOGICAL FUNCTION IN A MURINE MODEL OF SUBARACHNOID HEMORRHAGE Journal of Thrombosis and Haemostasis. 5: O-W-005-O-W-005. DOI: 10.1111/J.1538-7836.2007.Tb02469.X | 0.456 | |||
Show low-probability matches. |